Thermo Fisher Chosen by U.S. NIAID for Transplantation Trials

Thermo Fisher Scientific’s PPD clinical research business has been awarded a five-year contract to provide a Transplantation Statistical and Clinical Coordinating Center for the National Institute of Allergy and Infectious Diseases (NIAID). The center will provide support services for the design, development, execution, and analysis of transplantation clinical trials and research conducted by NIAID. Organ transplants reached a record high in 2021, with more than 40,000 performed, and over 100,000 people are on the national transplant waiting list. Thermo Fisher will leverage its expertise to assist sponsors in developing successful and cost-effective studies.

Thermo Fisher has also expanded its transplant diagnostics capabilities by opening the One Lambda Laboratories. The lab provides noninvasive, post-transplant testing services that aim to improve the long-term outcomes of transplant patients. These services include breakthrough assays that can detect rejection from at-home urine samples, potentially eliminating the need for invasive biopsies. The lab will also support research in developing new immunotherapies and immunosuppressive agents. Thermo Fisher aims to contribute to the advancement of transplantation science and improve the success of transplantation procedures.

Help improve our content system

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

Share this story:

Transplant News
Transplant News

Transplant News brings you the news and content that matters to the transplant community. From patient stories, to the latest in transplant innovation, Transplant News is your window into the world of transplantation.